These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15156302)

  • 1. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
    Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
    De Requena DG; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):555-9. PubMed ID: 15989460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between nevirapine plasma concentrations and abnormal liver function tests.
    Almond LM; Boffito M; Hoggard PG; Bonora S; Raiteri R; Reynolds HE; Garazzino S; Sinicco A; Khoo SH; Back DJ; Di Perri G
    AIDS Res Hum Retroviruses; 2004 Jul; 20(7):716-22. PubMed ID: 15307917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.
    Rakhmanina NY; Capparelli EV; van den Anker JN; Williams K; Sever JL; Spiegel HM; Soldin SJ
    Ther Drug Monit; 2007 Feb; 29(1):110-7. PubMed ID: 17304158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    De Maat MM; Mathôt RA; Veldkamp AI; Huitma AD; Mulder JW; Meenhorst PL; Van Gorp EC; Carlier H; Beijnen JH
    Pharmacol Res; 2002 Sep; 46(3):295-300. PubMed ID: 12220974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
    Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM
    HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    Núñez M; González-Requena D; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Chaix ML; Ekouevi DK; Peytavin G; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Amani-Bosse C; Menan H; Leroy V; Rouzioux C; Dabis F
    Antimicrob Agents Chemother; 2007 Mar; 51(3):896-901. PubMed ID: 17178792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
    Dailly E; Reliquet V; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2005 Apr; 61(2):153-6. PubMed ID: 15761750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission.
    Lau E; Brophy J; Samson L; Kakkar F; Campbell DM; Yudin MH; Murphy K; Seto W; Colantonio D; Read SE; Bitnun A
    J Acquir Immune Defic Syndr; 2017 Apr; 74(5):493-498. PubMed ID: 28114187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.
    Mugabo P; Els I; Smith J; Rabie H; Smith P; Mirochnick M; Steyn W; Hall D; Madsen R; Cotton MF
    S Afr Med J; 2011 Sep; 101(9):655-8. PubMed ID: 21920159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
    Dong BJ; Zheng Y; Hughes MD; Frymoyer A; Verotta D; Lizak P; Sawe F; Currier JS; Lockman S; Aweeka FT;
    AIDS; 2012 Apr; 26(7):833-41. PubMed ID: 22301417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.
    Mackie NE; Fidler S; Tamm N; Clarke JR; Back D; Weber JN; Taylor GP
    HIV Med; 2004 May; 5(3):180-4. PubMed ID: 15139985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.